Product Details

• Catalog Number: T0457
• Unit Size: 1 x 10⁶ cells / 1.0 ml
• Species: Human (Homo sapiens)
• Tissue Origin: Heart (Ventricular Cardiomyocytes)
• Donor Information: Female, Ventricle
• Cell Type: Immortalized Cardiomyocytes
• Growth Properties: Adherent, multipolar morphology
• Immortalization Method: Lentiviral transduction carrying SV40T
• Key Markers: GATA-4, ACTN2, ACTN3, MYH2, Puromycin-resistance
• Biosafety Level: BSL-2
• Storage Conditions: Vapor phase of liquid nitrogen (< -130°C)
• Shipping Conditions: Shipped on dry ice
• Format: Cryopreserved frozen cells
• Intended Use: Research use only. Not for human or therapeutic use.

Overview

Immortalized Human Cardiomyocytes – SV40T provide a robust cellular model to investigate cardiomyocyte biology. These cells have been immortalized to sustain extended proliferation while maintaining cardiac-specific markers and functions. They are ideal for applications in cardiovascular research, including signal transduction studies, drug testing, and cardiac toxicity assessment.

Key Features and Benefits

• Extended Culture Viability: Immortalized for prolonged culture without senescence.
• Reproducibility: Ensures consistency in experiments and assays.
• Physiologically Relevant Model: Expresses key cardiomyocyte-specific markers.
• Optimized Growth Conditions: Adapted to specific media and extracellular matrices for enhanced cell viability.
• Adherent Growth Properties: Enables easy handling and maintenance in standard culture settings.

Culture & Handling Guidelines

Recommended Culture Conditions

• Coating: Use PriCoat™ T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) for optimal adhesion..
• Growth Medium: PriGrow I (TM001) supplemented with:
  • 10% Fetal Bovine Serum (FBS)
  • 1% Penicillin/Streptomycin (G255)
• Incubation Conditions: Maintain at 37°C in a humidified atmosphere with 5% CO₂.
• Seeding Density: 20,000 – 30,000 cells/cm²
• Doubling Time: ~25–35 hours

Thawing Protocol

1. Thaw cells quickly in a 37°C water bath (maximum 2 minutes) while keeping the vial cap above the water level to minimize contamination.
2. Decontaminate the vial by spraying with 70% ethanol and transfer it to a biosafety cabinet.
3. Add the thawed cell suspension to a sterile 15 mL conical tube containing 5 mL of pre-warmed complete growth medium.
4. Centrifuge at 125xg for 5-7 minutes.
5. Aspirate the supernatant, gently resuspend the pellet in fresh complete growth medium, and seed into a pre-coated T25 flask.
6. Incubate under the recommended conditions until cells recover.

Subculturing Guidelines

1. Aspirate the old medium and rinse cells with PBS.
2. Add 2-3 mL of pre-warmed 0.25% Trypsin-EDTA and incubate at 37°C until cells detach (~2-10 minutes).
3. Neutralize Trypsin-EDTA by adding an equal volume of complete medium.
4. Centrifuge at 125xg for 5 minutes, aspirate the supernatant, and resuspend the pellet in fresh growth medium.
5. Seed cells at the appropriate density into new culture vessels.
6. Incubate under the recommended conditions and monitor for confluency.

Cryopreservation Guidelines

• Cryopreservation Medium: Complete growth medium supplemented with 10% DMSO.
• Freezing Protocol: Freeze at a controlled rate of -1°C per minute, then transfer to liquid nitrogen storage.

Related Products

• Recombinant Human VEGF (121aa) (E. coli) – Z102115
• Recombinant Human Beta-NGF – Z101545
• Recombinant Human TGF Beta-1 (TGFB1) – Z101555
• Recombinant Human IGF1 (E. coli) – Z100385

Disclaimer

1. This product is for research use only and is not intended for therapeutic, diagnostic, or clinical applications.
2. Performance may vary depending on the user’s culture conditions and adherence to recommended protocols.
3. The product must be stored and handled according to the provided conditions for optimal functionality.
4. The end-user assumes full responsibility for the suitability of this product for their specific research applications.
5. All sales are final. Live cell replacement may be available under specific conditions upon request.

Reference

1. Durham, Kristina K., et al. “HDL protects against doxorubicin-induced cardiotoxicity in a scavenger receptor class B type 1-, PI3K-, and Akt-dependent manner.” American Journal of Physiology-Heart and Circulatory Physiology 314.1 (2018): H31-H44.
2. Kono, Ken, et al. “Development of selective cytotoxic viral vectors for concentration of undifferentiated cells in cardiomyocytes derived from human induced pluripotent stem cells.” Scientific reports 9.1 (2019): 3630.